Influence of comorbidities on decision caring of malignant haematological diseases;Influence des polypathologies sur le traitement par des hémopathies malignes

Bulletin du Cancer

Volumn 96, Issue 5, 2009, Pages 563-570

  Najman, A ^a   Andre, K ^b   Gorin, N C ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b Clinact   (France)

Author keywords

Cancer; Comorbidity; Malignant hematological diseases; Older patients

Indexed keywords

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; COMORBIDITY; CORONARY ARTERY DISEASE; COST OF ILLNESS; DIABETES MELLITUS; DISEASE COURSE; FEMALE; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; KIDNEY FAILURE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; MYELOPROLIFERATIVE DISORDER; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PATIENT CARE; ADOLESCENT; BLOOD DISEASE; CHRONIC LYMPHATIC LEUKEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67650759928     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0857     Document Type: Article

References (19)

1. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. (editors). SEER Cancer Statistics Review, 1975-2004 National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
2. Guralnik JM. Assessing the impact of comorbidity in the older population. Ann Epidemiol 1996; 6: 376-380 (Pubitemid 26372525)
3. Extermann, M. Measurement and impact of comorbidity in older cancer patients (review). Crit Rev Oncol Hematol 2000; 35: 181-200. (Pubitemid 30674144)
4. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383 (Pubitemid 17055592)
5. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251 (Pubitemid 24361532)
6. Kaplan MH, Feinstein AR. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974; 27: 387-404.
7. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc 1995; 43: 130-137
8. Piccirillo JF, Tierney RM, Costas I, Grave L, Spitznagel Jr. EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-2447 (Pubitemid 38669187)
9. Van Spronsen DJ, Janssen-Heijnen MG, Breed WM, Coebergh JW. Prevalence of comorbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 1999; 78: 315-319
10. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919 (Pubitemid 41510773)
11. Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch G, et al. Hepatic injury after non myeloproliferative conditioning followed-by allogenic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78-84. (Pubitemid 38029921)
12. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587 (Pubitemid 28175784)
13. Cervantès F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684-690 (Pubitemid 28387050)
14. Von Hoff DD, Layard MW, Basa P, Davis Jr. HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91: 710-717 (Pubitemid 10218041)
15. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130: 1-7. (Pubitemid 38161241)
16. Stillwell TJ, Benson RC. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 1988; 61: 451-457 (Pubitemid 18039357)
17. Smith TJ, Khatcheressian J, Lyman JH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence based clinical practice guideline. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2006; 24: 3187-3205
18. Charlson M, Charlson RE, Briggs W, Hollenberg J. Can disease management target patients most likely to generate high costs? The impact of comorbidity. J Cen Intern Med 2007; 22: 464-469 (Pubitemid 46941213)
19. Yancik R, Ganz PA, Varrichio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 2001; 19: 1147-1151 (Pubitemid 32176292)